The key asset acquired was farabursen, an investigational oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat autosomal dominant polycystic kidney disease (ADPKD). Phase Ib trial results showed farabursen reduced kidney cyst growth and kidney size, supporting its potential as a first-in-class therapy for ADPKD.
Cyborg Score Rationale
Regulus was acquired by Novartis in June 2025 and is no longer an independent company. The score reflects the asset quality (strong lead candidate farabursen) but the entity itself is now integrated into Novartis.
Top Insights
(June 2025) Acquired by Novartis for $1.7 billion total consideration, including milestone-based contingent payments
Lead candidate farabursen shows Phase Ib efficacy in ADPKD with kidney size reduction and preferential kidney exposure
(April 2025) Original upfront payment was $7.00 per share in cash with additional $7.00 per share contingent on regulatory approval
MicroRNA-targeting technology platform addresses unmet needs in kidney disease and other therapeutic areas
Named Competitors
Capricor Therapeutics — Gene and cell therapy development
Inovio Pharmaceuticals — Immunotherapy and vaccine platform
Kite Pharma — CAR-T cell therapy and oncology
Recent Developments
(June 2025) Novartis completed acquisition of Regulus Therapeutics
(April 2025) Regulus entered into agreement to be acquired by Novartis
(2026) Novartis incorporated farabursen and Regulus assets into its renal disease pipeline under CEO Thomas Schinecker's stewardship
Open the full interactive Regulus Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.